Summary & Overview
HCPCS Level II J8501: Aprepitant, Oral, 5 mg
HCPCS Level II code J8501 denotes aprepitant, oral, 5 mg, an antiemetic agent used primarily in chemotherapy-induced nausea and vomiting prevention. Nationally, oral aprepitant is an important supportive oncology medication that affects pharmacy benefit management, outpatient clinic dispensing practices, and patient adherence to antiemetic regimens. Its billing and coverage implications influence total episode costs and patient out-of-pocket responsibility for antiemetic therapy.
Key payers included in this analysis are Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of payer coverage patterns, typical places of service where J8501 is billed, and common billing considerations. The publication outlines benchmarks for utilization and reimbursement where available, summarizes relevant policy updates affecting oral oncology supportive care drugs, and provides clinical context for aprepitant’s role in antiemetic protocols.
This summary is intended for national audiences interested in medical billing, pharmacy benefit management, and oncology supportive care policy. Data not available in the input is noted where applicable and does not affect the core description of the code and its clinical use.
Billing Code Overview
HCPCS Level II code J8501 represents aprepitant, oral, 5 mg. This code describes a prescription oral antiemetic formulation of aprepitant commonly used as part of chemotherapy-induced nausea and vomiting prophylaxis regimens.
Service Type: Oral medication administration / pharmacy-dispensed drug
Typical Site of Service: Outpatient pharmacy, clinic infusion center (dispensed for oral administration), or patient self-administered at home
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
Aprepitant, oral, J8501 (5 mg) is used as part of antiemetic prophylaxis for patients receiving moderately or highly emetogenic chemotherapy. A typical patient scenario: a 58-year-old female with newly diagnosed breast cancer scheduled to receive a moderately emetogenic chemotherapy regimen. The oncology clinic prescribes a multi-day antiemetic plan including a single oral dose of aprepitant 5 mg on day 1 in combination with a 5-HT3 antagonist and dexamethasone. Clinical workflow: the oncologist documents the chemotherapy regimen and antiemetic order; the infusion nurse verifies the oral aprepitant dose and documents administration in the medication administration record; the clinic billing staff assigns HCPCS Level II code J8501 for the oral aprepitant supply when billed as a separately payable drug or reported per payer guidance; appropriate modifiers are appended per payer requirements; medical record includes chemotherapy order, indication (chemotherapy-induced nausea and vomiting prophylaxis), and administration timing relative to chemotherapy.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
JW | Drug amount discarded/not administered | When part of the single-dose supply is discarded and payer requires reporting of discarded drug |